Doom and bloom.

Osimertinib isn’t going down without a fight. The phase 1 BLOOM study indicates this third-gen EGFR-TKI elicits a response in even the worst of the worse. Of 41 patients with EGFR-mutated NSCLC with leptomeningeal disease progressing on alternative EGFR-TKIs, nearly two-thirds responded to osimertinib, with an impressive median response time of 15 months. And patients will be happy to hear over half of those with neurologic symptoms clinically improved. | Yang, Clin Oncol 2020


Popular Posts